Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Dimopoulos, Meletios, MD, Siegel, David S, MD, Lonial, Sagar, MD, Qi, Junyuan, MD, Hajek, Roman, MD, Facon, Thierry, MD, Rosinol, Laura, MD, Williams, Catherine, MD, Blacklock, Hilary, MD, Goldschmidt, Hartmut, MD, Hungria, Vania, MD, Spencer, Andrew, MD, Palumbo, Antonio, MD, Graef, Thorsten, MD, Eid, Joseph E, MD, Houp, Jennifer, PharmD, Sun, Linda, PhD, Vuocolo, Scott, PhD, Anderson, Kenneth C, MD
Published in The lancet oncology (01.10.2013)
Published in The lancet oncology (01.10.2013)
Get full text
Journal Article
Graft Transit Time has no Effect on Outcome in Unrelated Donor Myeloablative Haematopoietic Cell Transplants (HCT) Performed in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) Study
Patton, William Nigel, MD, Nivison-Smith, Ian, Bardy, Peter, MD, Dodds, Anthony, MB BS FRACP, Ma, David, MD, PhD, Shaw, Peter John, MD, BMT, Kwan, John, MB BS FRACP FRCPA, Wilcox, Leonie, Butler, Andrew, Dr, Carter, John M., MD, Blacklock, Hilary, MD, Szer, Jeffrey, MBBS
Published in Biology of blood and marrow transplantation (01.03.2016)
Published in Biology of blood and marrow transplantation (01.03.2016)
Get full text
Journal Article